

Rula Zain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1594269/publications.pdf>

Version: 2024-02-01

37
papers

899
citations

643344

15
h-index

563245

28
g-index

39
all docs

39
docs citations

39
times ranked

1164
citing authors

#	ARTICLE	IF	CITATIONS
1	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. <i>Leukemia</i> , 2022, 36, 476-481.	3.3	25
2	Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101658.	3.9	28
3	Structural Insights into Human Adenovirus Type 4 Virus-Associated RNA I. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3103.	1.8	0
4	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13153.	1.3	5
5	2-((Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity. <i>Nucleic Acid Therapeutics</i> , 2022, , .	2.0	4
6	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. <i>Pharmaceutics</i> , 2021, 13, 116.	2.0	5
7	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. <i>Leukemia</i> , 2021, 35, 1317-1329.	3.3	35
8	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 630942.	1.8	119
9	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2021, 5, e564.	1.2	15
10	Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 694853.	2.2	30
11	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 443-456.	2.0	4
12	Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 804735.	2.2	1
13	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. <i>Blood Advances</i> , 2020, 4, 2439-2450.	2.5	15
14	Chemical Development of Therapeutic Oligonucleotides. <i>Methods in Molecular Biology</i> , 2019, 2036, 3-16.	0.4	14
15	Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases. <i>Neurotherapeutics</i> , 2019, 16, 248-262.	2.1	18
16	Oligonucleotide Binding to Non-B-DNA in MYC. <i>Molecules</i> , 2019, 24, 1000.	1.7	5
17	Oligonucleotide-Palladacycle Conjugates as Splice-Correcting Agents. <i>Molecules</i> , 2019, 24, 1180.	1.7	10
18	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. <i>PLoS ONE</i> , 2019, 14, e0211651.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. <i>Pharmaceutics</i> , 2019, 11, 666.	2.0	10
20	Therapeutic Oligonucleotides: State of the Art. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 605-630.	4.2	208
21	Combination of Gatekeeper Mutations and Cysteine 481 Replacement Causes Super Resistance to the Irreversible BTK Inhibitors Ibrutinib, Acalabrutinib and Zanubrutinib. <i>Blood</i> , 2019, 134, 5759-5759.	0.6	2
22	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 749-752.	1.0	8
23	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 132, 29-40.	2.0	17
24	Role of Pseudoisocytidine Tautomerization in Triplex-Forming Oligonucleotides: In Silico and in Vitro Studies. <i>ACS Omega</i> , 2017, 2, 2165-2177.	1.6	9
25	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. <i>Nucleic Acids Research</i> , 2017, 45, 5153-5169.	6.5	19
26	LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. <i>Scientific Reports</i> , 2017, 7, 11043.	1.6	28
27	Disruption of Higher Order DNA Structures in Friedreich's Ataxia (GAA) _n Repeats by PNA or LNA Targeting. <i>PLoS ONE</i> , 2016, 11, e0165788.	1.1	18
28	Four Novel Splice-Switch Reporter Cell Lines: Distinct Impact of Oligonucleotide Chemistry and Delivery Vector on Biological Activity. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 381-391.	2.0	12
29	Next-generation bis-locked nucleic acids with stacking linker and 2'-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. <i>Nucleic Acids Research</i> , 2016, 44, 2007-2019.	6.5	24
30	Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 183-189.	2.0	8
31	A Distinct Triplex DNA Unwinding Activity of ChlR1 Helicase. <i>Journal of Biological Chemistry</i> , 2015, 290, 5174-5189.	1.6	45
32	Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. <i>Nucleic Acids Research</i> , 2013, 41, 3257-3273.	6.5	25
33	Structure-Specific Recognition of Friedreich's Ataxia (GAA) _n Repeats by Benzoquinoxaline Derivatives. <i>ChemBioChem</i> , 2009, 10, 2629-2637.	1.3	20
34	Benzoquinoxaline Derivatives Stabilize and Cleave H-DNA and Repress Transcription Downstream of a Triplex-forming Sequence. <i>Journal of Molecular Biology</i> , 2005, 351, 776-783.	2.0	16
35	Triple-Helix Directed Cleavage of Double-Stranded DNA by Benzoquinoxaline-1,10-phenanthroline Conjugates. <i>ChemBioChem</i> , 2004, 5, 1550-1557.	1.3	33
36	Optimization of Triple-Helix-Directed DNA Cleavage by Benzoquinoxaline-Ethylenediaminetetraacetic Acid Conjugates. <i>ChemBioChem</i> , 2003, 4, 856-862.	1.3	9

#	ARTICLE	IF	CITATIONS
37	Design of a triple-helix-specific cleaving reagent. <i>Chemistry and Biology</i> , 1999, 6, 771-777.	6.2	48